Author:
Sperling Reisa A.,Jack Clifford R.,Black Sandra E.,Frosch Matthew P.,Greenberg Steven M.,Hyman Bradley T.,Scheltens Philip,Carrillo Maria C.,Thies William,Bednar Martin M.,Black Ronald S.,Brashear H. Robert,Grundman Michael,Siemers Eric R.,Feldman Howard H.,Schindler Rachel J.
Subject
Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology
Reference105 articles.
1. A single ascending dose study of bapineuzumab in patients with Alzheimer disease;Black;Alzheimer Dis Assoc Disord,2010
2. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease;Salloway;Neurology,2009
3. Risk Factors and clinical course associated with vasogenic edema in a phase II trial of bapineuzumab,2009
4. Sperling R, Bronen R, Greenberg S, Sorensen G, Salloway S, Gass A, et al. Three cases of apparent vasogenic edema (VE) from a Phase 2 clinical trial of the gamma secretase inhibitor BMS-708163 in patients with mild-to-moderate AD. Alzheimer's Association International Conference on Alzheimer's disease. Paris, France; 2011.
5. Cerebral hemorrhage after passive anti-Abeta immunotherapy;Pfeifer;Science,2002
Cited by
576 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献